Bronchodilator Drugs - Chile | Statista Market Forecast

The Bronchodilator Drugs market in Chile is expected to witness significant revenue growth in the coming years.
By 2024, the projected revenue is estimated to reach US$59.79m.
This growth is anticipated to continue, with an annual growth rate (CAGR 2024-2029) of 3.58%.
As a result, the market volume is projected to reach US$71.28m by 2029.
In comparison to other countries, United States is expected to generate the highest revenue in the Bronchodilator Drugs market.
By 2024, the revenue United States is estimated to reach US$17.34bn.
Chile's bronchodilator drug market is experiencing a surge in demand due to high levels of air pollution and a growing prevalence of respiratory diseases.

Definition:
Bronchodilator drugs help to dilate the airways, thus making air flow easier. They are mainly used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Bronchodilators may be applied in an acute therapy, leading to a fast and short-term relief of symptoms. Other types of bronchodilators are used for maintenance therapy in long-term treatment. Different categories of bronchodilators include beta two adrenergic agonists, anticholingergics, and theophylline.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim

Short-term and long-term bronchodilators
Treatment of asthma and COPD
Mode of administration: mainly inhalation powder (aerosolized or dry), but also nebulizers, intravenous administration, and oral intake
Bronchodilator combinations, e.g., several bronchodilators or a bronchodilator with a corticosteroid

Other drugs to treat asthma or COPD
Smoking cessation products
Alternative medicine

Bronchodilator drugs are widely used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In Chile, the market for bronchodilator drugs has been showing steady growth in recent years.

Customer preferences: Chile has a high prevalence of respiratory diseases, which has led to an increase in demand for bronchodilator drugs. The aging population and exposure to air pollution are among the main factors contributing to the high prevalence of respiratory diseases in the country. As a result, there is a growing demand for bronchodilator drugs that can provide quick relief from symptoms such as shortness of breath and wheezing.

Trends in the market: The bronchodilator drugs market in Chile is primarily driven by the increasing prevalence of respiratory diseases. The market is dominated by short-acting beta-agonists (SABAs) and long-acting beta-agonists (LABAs), which are the most commonly prescribed bronchodilator drugs in the country. The demand for combination therapies, which combine bronchodilators with other drugs such as corticosteroids, has also been increasing in recent years.

Local special circumstances: One of the unique features of the bronchodilator drugs market in Chile is the high level of competition among local and international pharmaceutical companies. The market is highly fragmented, with several small and medium-sized players competing with multinational companies. This has led to intense price competition, which has benefited consumers but has put pressure on profit margins for drug manufacturers.

Underlying macroeconomic factors: The Chilean economy has been growing steadily in recent years, which has led to an increase in disposable income and healthcare spending. The government has also been investing in healthcare infrastructure and expanding access to healthcare services, which has contributed to the growth of the bronchodilator drugs market. However, the market is also subject to regulatory risks, as the government has been implementing price controls on certain drugs in an effort to control healthcare costs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.